What is BillionToOne?
BillionToOne is a precision diagnostics company that utilizes a proprietary "molecular counter" platform to detect DNA molecules at a single-count level. Its primary mission is to make molecular diagnostics more accurate and accessible, notably by providing non-invasive, safe prenatal testing for single-gene disorders through blood tests, thereby avoiding the risks associated with invasive procedures like amniocentesis.
Related FAQs
BLLN is the ticker symbol for BillionToOne Inc., a molecular diagnostics company.
Yes, BillionToOne operates as a publicly traded enterprise. The molecular diagnostics and precision medicine company successfully completed its initial public offering on the NASDAQ Global Select Market, trading under the ticker symbol BLLN.
Bitdeer Technologies Group commands a corporate market capitalization of approximately $2.81 billion USD.
Financial tracking of BillionToOne encompasses private venture capital valuations and specialized biotech market metrics.
BillionToOne is widely regarded as an innovative, fast-growing molecular diagnostics and precision health company specializing in advanced prenatal screening and oncology liquid biopsy testing.
Yes, clinical tests offered by BillionToOne—such as its UNITY prenatal screen and Northstar oncology liquid biopsy panels—are widely covered by Medicare, Medicaid, and major private commercial health insurance providers.
Consensus analyst price targets for BillionToOne average approximately $123.86, with high-end institutional projections reaching up to $145.00 and conservative estimates around $90.00.
Yes, BillionToOne, Inc. is a publicly traded enterprise.
American Express Membership Rewards points possess a flexible valuation that varies significantly depending on how you choose to redeem them, meaning their cash value is not a fixed amount.
BillionToOne has evolved past its early-stage startup origins into a publicly traded commercial-stage molecular diagnostics enterprise.
BillionToOne is a molecular diagnostics enterprise that develops advanced, highly sensitive test technologies capable of analyzing DNA molecules down to single-nucleotide precision.
BillionToOne is a molecular diagnostics company headquartered in Menlo Park, California, United States.
BillionToOne's mission is centered on democratizing access to precision molecular diagnostics by engineering advanced testing platforms that are exceptionally accurate, fast, scalable, and affordable across healthcare systems.